GHRP-2, GHRP-6, Hexarelin, and Ibutamoren: Secretagogue Terminology
Direct answer: GHRP-2, GHRP-6 and hexarelin are peptide growth-hormone secretagogues. Ibutamoren belongs to the same broad secretagogue discussion but is a nonpeptide molecule. The group is defined by an experimentally studied signaling function, not by one shared chemical structure, and its receptor pathway differs from that of growth-hormone-releasing hormone.
A functional name can hide a chemical difference
A secretagogue is a substance that stimulates secretion in a biological system. “Growth-hormone secretagogue” therefore describes a functional category. It does not tell the reader whether a material is a peptide, which receptor interactions have been measured, or which experimental conditions produced the response.
This is why a category such as Growth Hormone Peptides needs more precise descriptions within it. The individual compounds remain distinct even when their names or research uses appear adjacent. Here the first separation is between peptide ligands and nonpeptide ligands; the second is between the secretagogue pathway and GHRH signaling.
The receptor story explains the terminology
In a 1996 study of secretagogue-binding sites, investigators examined structurally different secretagogues in pituitary membranes. Their binding observations supported a receptor system distinct from the GHRH receptor. The paper is useful because it connects a functional label to a receptor question rather than assuming that every GH-related signal has the same origin.
The later discovery of ghrelin by Kojima and colleagues identified an endogenous peptide ligand for the secretagogue receptor. The authors also showed that acylation was important to the activity of the isolated peptide. A natural ligand and synthetic ligands can help investigate the same receptor while retaining different molecular structures.
For a comparison with the other major pathway, the GHRH analogue guide explains why sermorelin and CJC-related materials should not simply be renamed GHRPs.
Four names that should remain four rows
| Name | Chemical category | Useful scientific distinction | Common interpretive mistake |
|---|---|---|---|
| GHRP-2 | Synthetic peptide secretagogue | A named ligand requiring its own assay evidence | Assigning GHRP-6 results because the abbreviation is similar |
| GHRP-6 | Synthetic peptide secretagogue | A distinct peptide in the receptor literature | Treating the number as a rank of activity |
| Hexarelin | Synthetic peptide secretagogue | Has also been examined for binding to CD36 | Describing all its reported interactions as GHS-R measurements |
| Ibutamoren, also associated with MK-677/MK-0677 naming | Nonpeptide secretagogue | Shared functional category does not imply a peptide structure | Calling every secretagogue a peptide |
The early receptor work supports the broader peptide/nonpeptide distinction. Compound-specific experimental work is needed to fill in a particular row; the table does not assert equal selectivity or equal responses.
GHRP-2 and GHRP-6 are names, not a progression
The numbers in GHRP-2 and GHRP-6 do not describe a dose, a generation of quality or a universal potency order. They identify different compounds. An article comparing them should state what changed in the experiment rather than using the names themselves as evidence.
For example, a secretion measurement concerns the response of the experimental system. A binding measurement concerns an interaction with the assay target. If one paper reports secretion and another reports binding, placing the two numbers in adjacent cells does not turn them into a head-to-head comparison. The endpoint, reference ligand and biological preparation need to agree before a numerical contrast becomes meaningful.
The same caution applies to selectivity. A study can demonstrate a response at one tested receptor without testing every other possible interaction. “Active at” and “exclusive to” are different statements.
Hexarelin shows why the assay target matters
The photoaffinity study of hexarelin and CD36 investigated a binding region on a protein distinct from the growth-hormone secretagogue receptor. Its value here is the demonstration that a familiar ligand name can appear in a different receptor experiment.
For Hexarelin, a summary should therefore name the target attached to the finding. A CD36-binding observation cannot be silently rewritten as a measurement of pituitary GH secretion. Conversely, a secretion result does not establish the detailed binding mechanism described in a photolabeling experiment. Keeping those questions apart makes the literature more interesting and more precise, rather than reducing every paper to the same pathway label.
How this differs from a CJC-1295 comparison
CJC-related materials enter the discussion through GHRH-analogue terminology. Putting them next to a secretagogue can be a useful comparison of pathways, but does not make them chemically related or experimentally interchangeable. The CJC-1295 and ipamorelin article develops that distinction for a commonly paired set of names.
When comparing papers, write down whether the investigators measured the ligand, the receptor response, hormone secretion or a later endpoint. These are successive questions, not synonyms. A finding at one level may motivate testing at another level; it does not supply that missing result.
From a compound name to an analytical question
The NEXTWAVE PEPTIDES catalog identifies the specific product being considered. Its matching COA addresses the measurements reported for a sample, while the scientific papers address their experimental hypotheses. For example, an identity result and a purity result do not establish receptor selectivity. The peptide COA guide explains how to read those analytical distinctions without expanding a laboratory report into a biological claim.
Limits of this comparison
The sources discussed here were selected to explain receptor terminology and distinct experimental questions. They are not an exhaustive assessment of every compound, outcome or study population. Early receptor experiments and later binding studies use different biological preparations and cannot be pooled into a single performance ranking. This article gives no administration instructions and does not treat a published experiment as verification of a commercial batch.
FAQ
Is ibutamoren a peptide because it is a secretagogue?
No. Secretagogue is a functional description. The cited receptor literature includes both peptide ligands and nonpeptide molecules.
Is GHRP another name for GHRH?
No. The terminology refers to different ligand groups and receptor pathways. Similar downstream interests do not erase that distinction.
Does GHRP-6 mean it is stronger than GHRP-2?
No. The numbers are part of the names. Any comparison needs a defined endpoint and comparable experimental conditions.
Why mention CD36 in an article about hexarelin?
Because a primary study examined hexarelin binding at CD36. Naming that target prevents its findings from being confused with a different receptor assay.